Release
2021/11/25
OSAKA, Japan, 25, November, 2021 - Shionogi & Co., Ltd. (hereafter "Shionogi") announced Shionogi has concluded a memorandum of understanding (hereafter "MoU") with the ADMINISTRATION OF SCIENCE, TECHNOLOGY AND TRAINING - THE MINISTRY OF HEALTH OF THE SOCIALIST REPUBLIC OF VIETNAM (hereinafter "ASTT") for infectious disease control, including COVID-19.
In accordance with this MoU, the ASTT, the Advanced International Joint Stock Company (hereafter "AIC") and Shionogi will continue to discuss cooperation for infectious disease control, including control of COVID-19. Regarding COVID-19, which remains a global crisis, the collaboration will include clinical trials of Shionogi’s recombinant protein-based COVID-19 vaccine (S-268019) and its oral therapeutic agent (S-217622) in Vietnam, as well as technology transfer for the manufacture of S-268019 in Vietnam. The MoU will provide the basis formore specific discussions between the three parties.
Shionogi is committed to “Protect people worldwide from the threat of infectious diseases” as our key focus. As COVID-19 continues to have a major impact on people’s lives and to represent a worldwide threat, Shionogi recognizes Japan's global role in addressing this pandemic by contributing to effective countermeasures, which is fully aligned with our own mission as a company dedicated to the control of infectious diseases. Therefore, we will work with the Vietnam government and local partners to control infectious diseases, including COVID-19.
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html